Takara Bio to Release Two New Enzymes.Tokyo, Japan, June 5, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takara Bio announced on June 1 that it will begin marketing two new enzymes, PrimeSTAR Max DNA Polymerase DNA polymerase /DNA po·lym·er·ase/ (pah-lim´er-as) any of various enzymes catalyzing the template-directed incorporation of deoxyribonucleotides into a DNA chain, particularly one using a DNA template. and PrimeScript, on June 18. A polymerase chain reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) ) enzyme, PrimeSTAR Max DNA Polymerase has increased DNA amplification efficiency. Specifically, it can reduce the time required for amplification by 80%. Targeting the high-throughput screening and genetic testing markets, the company aims to generate annual sales of 100 million yen ($900,000). A reverse transcriptase enzyme used in gene expression analysis, PrimeScript can synthesize cDNA in an efficient fashion. The company aims to achieve annual sales of 200 million yen ($1.8 mil), including sales of related products such as RT-PCR RT-PCR reverse transcriptase-polymerase chain reaction. See PCR1. kits and reagents. Takara Bio aims to consolidate its presence in the domestic PCR enzyme market by increasing sales with the two new products. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion